Health In Tech, Inc. (HIT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 51/100 (HIGH), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.06% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Health In Tech to Attend the 17th Annual Craig-Hallum Alpha Select Conference
- Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026
- HIT: Contracted & Pipeline Revenue Leading Indicators That Arguably Point to Strong Prospects
- Health In Tech (HIT) Q2 2026 Earnings Call Transcript
- Health In Tech Inc (HIT) (Q2 2026) Earnings Call Highlights: Strategic Carrier Shift and Hitrix ...
- Health In Tech Q2 Earnings Call Highlights
- /C O R R E C T I O N -- Health In Tech, Inc./
- Health In Tech Added to Membership of Russell Microcap® Index
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Health In Tech, Inc..
Full HIT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.